Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant was named a gold award winner at the 13th annual Stevie Awards for Women in Business in the category of "Best New Product or Service of the Year."
Behshad Sheldon, president and CEO of Titan’s marketing partner, Braeburn Pharmaceuticals, was also selected as a bronze award winner in the category of "Best Female Executive of the Year."
Gold award winner Probuphine is a six-month buprenorphine implant for the maintenance treatment of opioid addiction.
Under Ms. Sheldon's leadership, Probuphine advanced through clinical development and received FDA approval for commercialization in May 2016. Braeburn is also developing six late-stage product candidates and two earlier-stage product candidates, all of which are either injectables or implants.
"Our company has a robust pipeline of treatments for patients who are often neglected and stigmatized by society, yet who deserve the same level of innovation that is dedicated to other chronic diseases,” Ms. Sheldon said in a statement.